CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...
For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise ...
1910's CANDID-CNS™ AI model has been published in the Journal of Chemical Information and Modeling (JCIM), a journal of the American Chemical Society. CANDID-CNS™ is the new state-of-the-art AI model ...
1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced that its CANDID-CNS™ AI model has been published in the Journal of Chemical Information and ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
The MarketWatch News Department was not involved in the creation of this content. -- CANDID-CNS(TM) is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback